Cristal Therapeutics is a pharmaceutical company developing superior products based on its proprietary CriPec® platform. Cristal Therapeutics’ mission is to improve the therapeutic performance of drugs resulting in commercial opportunities in various disease areas. The application of CriPec® potentially results in a better efficacy and enhanced tolerability due to an improved disposition. The first product that is independently being developed by Cristal Therapeutics is CriPec® docetaxel for the treatment of solid tumours. The company is founded in April 2011 and based in Maastricht, The Netherlands